metabolic syndrome
Conditions
Interventions
This is a prospective and randomized study to assess the effect of ezetimibe on visceral fat in patients with metabolic syndrome. After baseline assessment, patients are instructed to modify their lif
Sponsors
Enshu Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged >= 20 years with both metabolic syndrome and elevated low-density lipoprotein (LDL)-cholesterol levels (>= 120 mg/dL) were eligible for the present study if they were in a stable condition and any antihypertensive, antidyslipidaemic, and/or antidiabetic medications had not been changed for at least 4 weeks prior to the start of the study.
Exclusion criteria
Exclusion criteria: The exclusion criteria were: use of insulin, a history of hypersensitivity to ezetimibe, acute coronary syndrome and brain attacks (infarction or haemorrhage) within 3 months, secondary dyslipidaemia, familiar hypercholesterolaemia, pregnancy and severe hepatic, renal, active inflammatory and malignant diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in visceral fat on CT from baseline to 6 months after randomization | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in lipid profiles, glucose metabolism, body weight, waist circumference, subcutaneous fat, and improvement of hepatic steatosis | — |
Countries
Japan
Outcome results
None listed